IntroductionLeukocyte-platelet cross-talk plays multiple and important roles in inflammatory and thrombotic responses. 1 Activated platelets and platelet-released mediators, such as PDGF and PAF, activate leukocytes enhancing their responses such as adhesion, chemotaxis, phagocytosis, and superoxide generation. [2][3][4][5] Conversely, activated leukocytes induce platelet activation as evidenced by increased platelet P-selectin expression. 6 In vivo studies show that leukocytes and platelets colocalize within atherosclerotic and restenotic lesions, at sites of hemorrhage and ischemia-reperfusion injury. [7][8][9][10] Indeed, increased levels of leukocyte-platelet aggregates are found in patients with diabetes, acute coronary syndromes, trauma, and sepsis. [11][12][13] Numerous studies have analyzed the receptors involved in leukocyte-platelet interactions. P-selectin on activated platelets binds PSGL-1 on leukocytes 14,15 to support their rolling on adherent platelets and to activate leukocyte integrin ␣ M  2 , which mediates firm leukocyte adhesion. [16][17][18] Several ␣ M  2 counterreceptors on platelets have been proposed, including Fg-bound ␣ IIb  3 , 19 GPIb␣,20,21 and JAM-3. 22 Recognition of these counterreceptors requires that ␣ M  2 be in an activated conformation. ␣ M  2 can be activated by stimulation of leukocytes by agonists and can be monitored with monoclonal antibodies (mAbs), CBRM1/5 and mAb24, which react selectively with the activated conformation.Microparticles (MPs) are released by membrane blebbing from cells undergoing activation or apoptosis. MPs are usually defined by 2 criteria: size (Ͻ 1 m) and surface expression of negatively charged phosphatidylserine (reviewed in Boulanger et al, 23 Morel et al, 24 Martinez et al, 25 and Distler et al 26 ). MPs are not simply the markers of cell activation or damage but may exert pleiotropic effects on blood and vascular cells. MPs of platelet and endothelial origin have procoagulant and proinflammatory activities (reviewed in Boulanger et al, 23 Morel et al, 24 Martinez et al, 25 and Distler et al 26 ) and are markers of acute coronary syndromes. 27,28 The functions of leukocyte-derived MPs are less clear. MPs shed by PMNs behave as inflammatory mediators and activate endothelial cells 29,30 but also exert antiinflammatory effects on macrophages. 31 One of the most important features of leukocyte-derived MPs is the expression of tissue factor 32 and negatively charged phospholipids, suggesting that they may contribute to blood coagulation. Indeed, in vivo studies have shown that leukocyte MPs are captured by activated platelets within thrombi by a P-selectin/PSGL-1-dependent mechanism that leads to accumulation of tissue factor and ultimately enhanced fibrin deposition. 33,34 Although the interactions of leukocyte-derived MPs with activated platelets have been well documented, additional mechanisms in which leukocyte MPs may activate resting platelets, when platelet P-selectin expression is low, have not been examined. In this study, we show...